Bone Biologics (NASDAQ:BBLG – Get Free Report) is expected to release its results before the market opens on Friday, November 13th. Analysts expect Bone Biologics to post earnings of ($0.19) per share for the quarter.
Bone Biologics (NASDAQ:BBLG – Get Free Report) last released its quarterly earnings data on Monday, October 26th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02. On average, analysts expect Bone Biologics to post ($1.18) EPS for the current fiscal year and ($0.59) EPS for the next fiscal year.
Bone Biologics Trading Up 2.6%
NASDAQ:BBLG opened at $0.35 on Thursday. Bone Biologics has a one year low of $0.32 and a one year high of $2.39. The firm’s fifty day moving average price is $0.45 and its two-hundred day moving average price is $1.01.
Analyst Ratings Changes
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bone Biologics in a research note on Thursday, October 22nd. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.
View Our Latest Stock Analysis on Bone Biologics
About Bone Biologics
Bone Biologics Corporation is a biotechnology and medical device company focused on developing regenerative products for bone repair and spinal fusion. Its technology platform is based on NELL-1, a recombinant human protein designed to stimulate bone growth and support the formation of new bone. The company’s lead development programs combine NELL-1 with resorbable bone-graft scaffolds for use in orthopedic and spinal procedures. These products are intended to provide surgeons with alternatives or supplements to conventional bone-grafting approaches, with an initial emphasis on spinal fusion applications.
Read More
- Five stocks we like better than Bone Biologics
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
